Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

Presentation TCT 2017

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Presenter: Brij Maini, Petr Neuzil, Grzegorz Smolka, MD

October 31, 2017

Presentation TCT 2017

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

Presentation iASSESS 2017

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Presenter: Dmitriy N. Feldman

August 30, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

Presentation

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

August 07, 2017

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

Presentation JIM 2017

The Future of Long Term Antiplatelet therapy: Is life Long Aspirin Still Necessary?

Presenter: Roxana Mehran

February 10, 2017

Advertisement

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

TCT 76: Impact of Post-Discharge Dual Antiplatelet Therapy vs Aspirin Alone After CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Aspirin and ADP Antagonists Pre and Post Coronary Stent Implantation

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With DES

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

The Future of Long Term Antiplatelet therapy: Is life Long Aspirin Still Necessary?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content